<DOC>
	<DOCNO>NCT00106418</DOCNO>
	<brief_summary>The purpose study evaluate activity romidepsin ( depsipeptide , FK228 ) patient metastatic prostate cancer develop rise prostate specific antigen ( PSA ) undergo hormonal therapy .</brief_summary>
	<brief_title>A Research Study Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Males ≥18 year ; Written inform consent/authorization ; Histological cytological confirmation metastatic prostate cancer document progression hormonal therapy ( objective progressive disease [ PD ] , new bone lesion , stable soft tissue bone lesion PSA increase ) ; Patients must either measurable disease bone metastasis . Patients measurable disease prefer ; Rising PSA , minimum study entry PSA ≥5 ng/mL ; Karnofsky performance status ≥80 % ; Life expectancy &gt; 12 week ; For patient treated antiandrogens , elevation PSA must demonstrate cessation antiandrogen treatment ; Three line hormonal therapy permit prior study entry ( antiandrogen withdrawal consider second hormonal treatment ) ; Serum testosterone level &lt; 50 ng/mL patient without surgical castration ; Patients must serum potassium level &gt; 4.0 mEq/L serum magnesium level &gt; 2.0 mg/dL . Concomitant use anticancer therapy , except continue use luteinizing hormonereleasing hormone ( LHRH ) agonists antiandrogens , bisphosphonates steroid initiate least 4 week prior study entry ; Concomitant use investigational agent , include PCSPES ; Use investigational agent within 4 week study entry ; Concomitant use warfarin ( due potential drugtodrug interaction depsipeptide ) ; Major surgery within 2 week study entry ; Prior treatment chemotherapy ; Patients know cardiac abnormality : Congenital long QT syndrome ; QTc interval &gt; 480 millisecond ; Patients myocardial infarction within 12 month study entry ; Patients history coronary artery disease ( CAD ) e.g. , angina Canadian Class II IV ( see Appendix K ) . In patient doubt , patient stress image study , abnormal , angiography define whether CAD present ; Patients ECG record screen show evidence cardiac ischemia ( ST depression ≥2 mm ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present ; Patients congestive heart failure meet NYHA Class II IV ( see Appendix J ) definition and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or magnetic resonance imaging ( MRI ) ; Patients history sustain VT , VF , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; Patients hypertrophic cardiomegaly restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) ; Patients uncontrolled hypertension i.e. , ≥160/95 ; Patients cardiac arrhythmia require antiarrhythmic medication ; Concomitant use medication may cause prolongation QT/QTc ( see Appendix D ) interval ; Concomitant use medication inhibitor cytochrome P450 isoenzyme CYP 3A4 ( see Appendix E ) ; Clinically significant active infection ; Known infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C ; Previous extensive radiotherapy involve 30 % bone marrow ( e.g. , whole pelvis , half spine ) ; Clinical radiological imaging evidence brain metastasis ( compute tomography [ CT ] MRI scan require brain metastasis suspect clinically ) ; Inadequate bone marrow organ function , evidence : hemoglobin &lt; 9.0 g/dL ( transfusion and/or erythropoietin permit ) ; absolute neutrophil count ( ANC ) ≤1.5 x 109 cells/L ; platelet count &lt; 100 x 109 cells/L ; total bilirubin &gt; 1.25 x upper limit normal ( ULN ) institution &gt; 2.0 x ULN presence demonstrable liver metastasis ; aspartate transaminase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine transaminase/serum glutamic pyruvic transaminase ( ALT/SGPT ) &gt; 2.0 x ULN &gt; 5.0 x ULN presence demonstrable liver metastasis ; serum creatinine &gt; 2 mg/dL ; Serum potassium level &lt; 4.0 mEq/L serum magnesium level &lt; 2.0 mg/dL ; Coexistent second malignancy history prior malignancy within previous 5 year ( exclude basal squamous cell carcinoma skin treat curatively ) ; Any significant medical psychiatric condition might prevent patient comply study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen independent metastatic prostate cancer patient rise PSA</keyword>
	<keyword>romidepsin</keyword>
</DOC>